N/A
Completed N=112
Neuroprotective Goal Directed Hemodynamic Optimization in Post-cardiac Arrest Patients
Source: ClinicalTrials.gov NCT02541591 ↗Enrolled (actual)
112
Serious AEs
26.2%
Results posted
Apr 2024
Primary outcomePrimary: % of Ischaemic Voxels With an ADC<0.65 mm2/s on Day 4-5 (Diffusion Weighted MRI) — 10.6; 11.0 percentage of ischaemic voxels — p=0.0881
Summary
The primary objective of the Neuroprotect trial is to assess whether or not a new goal directed hemodynamic optimization strategy can reduce cerebral ischemia in post-cardiac arrest (CA) patients.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY % of Ischaemic Voxels With an ADC<0.65 mm2/s on Day 4-5 (Diffusion Weighted MRI) |
10.6; 11.0 | 0.0881 |
Eligibility Criteria
Inclusion Criteria
- Out-of-hospital CA of presumed cardiac cause irrespective of the presenting rhythm
- Unconsciousness (Glasgow coma scale 1 mcg/kg/min).
- Open chest
- ECMO (extracorporeal membrane oxygenation)
- Pregnancy
Data sourced from ClinicalTrials.gov (NCT02541591). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.